cjc1295 no dac ipamorelin CJC-1295 (No DAC) + 5MG/5MG Third party lab tested with a certificate of analysis CJC-1295 No DAC + Ipamorelin

After 12 months of using 2 mg of tesamorelin via subcutaneous injection, researchers noticed a sustained decrease in visceral adipose tissue in the test subjects

Improving Bone Density and Regeneration Another highly common symptom of the aging process that can be reversed with this treatment is a decrease in bone density

doi:10.1530/eje.0.1390552 Falutz J, Mamputu JC, Potvin D, et al

Comparison CompoundClassPathway / targetResearch focusFormat CJC-1295 DACGHRH analogueGHRH receptorSustained GH pulse researchVial CJC-1295 (no DAC)GHRH analogueGHRH receptorShort-acting GH pulse researchVial IpamorelinGH secretagogueGHS-R (ghrelin receptor)Selective GH pulse researchVial SermorelinGHRH analogueGHRH receptorGH-axis researchVial TesamorelinGHRH analogueGHRH receptorVisceral-fat / IGF-1 axis researchVial CJC-1295 no DAC + IpamorelinGHRH analogue + GH secretagogue blendGHRH receptor / GHS-RCombined GH pulse researchVial Every compound in this category is supplied as Research Use Only material with: Peer-reviewed literature underpinning this category

You can find the quiz here